Inhibikase Therapeutics Inc. Common Stock (IKT)

About IKT

Sector

Health Care

Industry

Biotechnology: Biological Products (No Diagnostic Substances)

Website

www.inhibikase.com/

Fundamentals

Market cap

$318.20M

P/E (trailing)

—

P/E (forward)

—

EPS (trailing)

$-1.15

Dividend yield

—

Beta

0.91

Avg. volume

—

Inhibikase Therapeutics Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• IKT

  Inhibikase Therapeutics Inc. Common Stock

  $2.42

  ▼ 2.23%
  Market cap $318.20MP/E —
  $1.33$2.54
• AVXL

  Anavex Life Sciences Corp. Common Stock

  $2.98

  ▼ 4.79%
  Market cap $303.96MP/E —
  $2.26$10.4
• NMRA

  Neumora Therapeutics Inc. Common Stock

  $1.38

  ▼ 6.76%
  Market cap $303.87MP/E —
  $0.83015$3.65
• AGEN

  Agenus Inc. Common Stock

  $7.67

  ▼ 1.79%
  Market cap $335.19MP/E 4.88
  $2.71$8.85
• SABS

  SAB Biotherapeutics Inc. Common Stock

  $3.79

  ▼ 3.56%
  Market cap $294.39MP/E 26.94
  $1.85$5.15
• IPSC

  Century Therapeutics Inc. Common Stock

  $2.03

  ▼ 9.19%
  Market cap $342.67MP/E —
  $0.435$3.04
• FATE

  Fate Therapeutics Inc. Common Stock

  $2.42

  ▼ 4.92%
  Market cap $290.23MP/E —
  $0.93$3.23

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• Inhibikase Therapeutics Q2 EPS $(0.11), Inline
  benzinga · 8/11/2026
• Inhibikase Therapeutics Q2 EPS $(0.11), Inline
  Benzinga · 8/11/2026

• Dennis N. Berman · July 30, 2026 · Option Exercise

  21.9K @ $1.26
• RA CAPITAL MANAGEMENT, L.P. · July 29, 2026 · J

  18.03M

Institutional Ownership

March 31, 2026

Total shares held

112.45M

Total value held

$188.53M

Institutional holders

100